U.S. markets open in 4 hours 50 minutes

ZimVie Inc. (ZIMV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
16.18-1.27 (-7.28%)
At close: 04:00PM EDT
16.33 +0.15 (+0.93%)
After hours: 06:32PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close17.45
Bid0.00 x 900
Ask0.00 x 900
Day's Range15.83 - 18.11
52 Week Range15.83 - 50.40
Avg. Volume362,632
Market Cap421.974M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.66
Earnings DateMay 05, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ZIMV

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ZimVie Inc.
    ZIMV: What does Argus have to say about ZIMV?ZIMVIE INC has an Investment Rating of BUY; a target price of $21.000000; an Industry Subrating of High; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of High.
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • GlobeNewswire

    ZimVie Announces Launch of Two Next-Generation Dental Solutions in the United States

    T3® PRO Tapered Implant and the Encode® Emergence Healing Abutment designed to optimize restorative care and aestheticsWESTMINSTER, Colo., June 16, 2022 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced the joint launch of the new, FDA-cleared T3® PRO Tapered Implant and Encode® Emergence Healing Abutment in the United States. The T3 PRO is the newest addition to ZimVie’s family of dental implants and builds on the prov

  • Simply Wall St.

    How Much Of ZimVie Inc. (NASDAQ:ZIMV) Do Institutions Own?

    The big shareholder groups in ZimVie Inc. ( NASDAQ:ZIMV ) have power over the company. Institutions will often hold...

  • GlobeNewswire

    ZimVie Reports First Quarter 2022 Financial Results

    Third party net sales of $234.7 million, inclusive of $120.6 million in dental net sales and $114.1 million in spine net salesNet loss of ($25.7) million; net loss as a percentage of net sales of (10.9%); adjusted net income[1] of $13.1 millionDiluted EPS of ($0.98); adjusted diluted EPS of $0.50[1]Adjusted EBITDA[1] of $33.8 million; adjusted EBITDA margin[1] of 14.4% Cash balance of $104.3 million at March 31, 2022 WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV)